393 related articles for article (PubMed ID: 35589257)
1. Promises of microbiome-based therapies.
Bajaj JS; Ng SC; Schnabl B
J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
[TBL] [Abstract][Full Text] [Related]
2. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
[TBL] [Abstract][Full Text] [Related]
3. Microbiome as a therapeutic target in alcohol-related liver disease.
Sarin SK; Pande A; Schnabl B
J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
[TBL] [Abstract][Full Text] [Related]
4. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
5. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
[TBL] [Abstract][Full Text] [Related]
6. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
7. The role of the microbiome in liver disease.
Schöler D; Schnabl B
Curr Opin Gastroenterol; 2024 May; 40(3):134-142. PubMed ID: 38362864
[TBL] [Abstract][Full Text] [Related]
8. Gut dysbiosis and age-related neurological diseases; an innovative approach for therapeutic interventions.
Holmes A; Finger C; Morales-Scheihing D; Lee J; McCullough LD
Transl Res; 2020 Dec; 226():39-56. PubMed ID: 32755639
[TBL] [Abstract][Full Text] [Related]
9. Roles for the mycobiome in liver disease.
Zeng S; Schnabl B
Liver Int; 2022 Apr; 42(4):729-741. PubMed ID: 34995410
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
11. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
Leclercq S; de Timary P; Stärkel P
Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
[TBL] [Abstract][Full Text] [Related]
12. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care.
Ciernikova S; Sevcikova A; Drgona L; Mego M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188990. PubMed ID: 37742728
[TBL] [Abstract][Full Text] [Related]
13. Contribution of gut microbiota to drug-induced liver injury.
Chu HK; Ai Y; Cheng ZL; Yang L; Hou XH
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):458-465. PubMed ID: 37365109
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.
Yadav A; Yadav R; Sharma V; Dutta U
Indian J Gastroenterol; 2024 Feb; 43(1):112-128. PubMed ID: 38409485
[TBL] [Abstract][Full Text] [Related]
15. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
16. Application of Microbiome-Based Therapies in Chronic Respiratory Diseases.
Lee SH; Lee JH; Lee SW
J Microbiol; 2024 Mar; 62(3):201-216. PubMed ID: 38635003
[TBL] [Abstract][Full Text] [Related]
17. Gut Microbiota and Diarrhea: An Updated Review.
Li Y; Xia S; Jiang X; Feng C; Gong S; Ma J; Fang Z; Yin J; Yin Y
Front Cell Infect Microbiol; 2021; 11():625210. PubMed ID: 33937093
[TBL] [Abstract][Full Text] [Related]
18. Roles of the gut virome and mycobiome in faecal microbiota transplantation.
Lam S; Bai X; Shkoporov AN; Park H; Wu X; Lan P; Zuo T
Lancet Gastroenterol Hepatol; 2022 May; 7(5):472-484. PubMed ID: 35276080
[TBL] [Abstract][Full Text] [Related]
19. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?
Hatton G; Shawcross DL
Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):1-2. PubMed ID: 30791837
[No Abstract] [Full Text] [Related]
20. Restoration of dysbiotic human gut microbiome for homeostasis.
Dixit K; Chaudhari D; Dhotre D; Shouche Y; Saroj S
Life Sci; 2021 Aug; 278():119622. PubMed ID: 34015282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
